Infliximab therapy in children with Crohn's disease: A one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies

Acta Paediatrica, International Journal of Paediatrics

Volumn 100, Issue 3, 2011, Pages 451-455

  Kim, Mi Jin ^a   Lee, Jong Seung ^a   Lee, Ji Hyuk ^a   Kim, Jae Young ^b   Choe, Yon Ho ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Children; Crohn's disease; Infliximab; Step up vs. Top down strategy

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MESALAZINE; PREDNISOLONE; SERUM ALBUMIN;

ADOLESCENT; ANOREXIA; ANUS FISTULA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; PANCREATITIS; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; TACHYCARDIA;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79551601075     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2010.01938.x     Document Type: Article

References (23)

1. Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98: 833-8.
2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
3. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
4. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN,. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104-11.
5. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009; 15: 816-22.
6. Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A,. Infliximab in Crohn's disease: early and long-term treatment. Dig Liver Dis 2008; 40 Suppl 2: S271-9.
7. Devlin SM, Panaccione R,. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am 2009; 38: 577-94.
8. Meier J, Sturm A,. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease]. Z Gastroenterol 2009; 47: 240-2.
9. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
10. IBD Working Group of the European Society for Paediatric Gastroenterology Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis - the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7.
11. Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005; 41: 416-21.
12. Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM,. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology 1999; 116: 527-31.
13. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114-22.
14. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
15. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69.
16. Munkholm P, Langholz E, Davidsen M, Binder V,. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
17. Hyams JS, Markowitz J, Wyllie R,. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137: 192-6.
18. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F,. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
19. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73. (Pubitemid 46454266)
20. Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: 265-9.
21. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7. (Pubitemid 24317633)
22. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
23. Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P,. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma 2007; 48: 1410-3.